Yonsung

Yonsung Fine Chemical is a South Korean pharmaceutical company specializing in the development and manufacture of high-potency Active Pharmaceutical Ingredients (APIs), with a particular global leadership in prostaglandin derivatives. Established in 1994, the company offers comprehensive CDMO services, including custom synthesis and process development, supported by cGMP-compliant manufacturing facilities. Their product portfolio includes key treatments for glaucoma, cardiovascular diseases, and gastrointestinal disorders, exported to major markets such as the United States, Europe, and Japan. In 2023, the company was acquired by SK Chemicals to strengthen its global presence in the specialized API market.